Adamas Pharmaceuticals, Inc. (ADMS) Reaches $33.81 After 4.00% Down Move; 3 Analysts Are Bullish Vince Holding Corp. (VNCE) Last Week

February 15, 2018 - By Ellis Scott

Among 6 analysts covering Vince Holding (NYSE:VNCE), 3 have Buy rating, 1 Sell and 2 Hold. Therefore 50% are positive. Vince Holding had 13 analyst reports since September 2, 2015 according to SRatingsIntel. Robert W. Baird maintained it with “Neutral” rating and $7 target in Friday, September 4 report. As per Friday, September 4, the company rating was maintained by Barclays Capital. Stifel Nicolaus maintained the stock with “Buy” rating in Tuesday, January 10 report. The firm has “Underperform” rating given on Friday, September 4 by Bank of America. The firm has “Overweight” rating given on Monday, August 22 by Piper Jaffray. PiperJaffray upgraded the stock to “Buy” rating in Monday, August 22 report. B. Riley & Co maintained Vince Holding Corp. (NYSE:VNCE) on Friday, September 4 with “Neutral” rating. Stifel Nicolaus upgraded Vince Holding Corp. (NYSE:VNCE) on Monday, December 5 to “Buy” rating. See Vince Holding Corp. (NYSE:VNCE) latest ratings:

The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) is a huge mover today! The stock decreased 3.50% or $1.23 during the last trading session, reaching $33.81. About 379,913 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has declined 0.40% since February 15, 2017 and is downtrending. It has underperformed by 17.10% the S&P500.The move comes after 9 months negative chart setup for the $884.81 million company. It was reported on Feb, 15 by Barchart.com. We have $32.46 PT which if reached, will make NASDAQ:ADMS worth $35.39M less.




Vince Holding Corp. engages in the design, merchandise, and sale of various luxury brand products in the United States and internationally. The company has market cap of $92.03 million. It operates through two divisions, Wholesale and Direct-To-Consumer. It currently has negative earnings. The firm offers a range of womenÂ’s products, such as cashmere sweaters, silk blouses, leather and suede leggings and jackets, dresses, denims, pants, tanks, T-shirts, handbags, and outerwear under the Vince brand; and menÂ’s products comprising T-shirts, knit and woven tops, sweaters, denim, pants, blazers, outerwear, and leather jackets under the Vince brand.

Investors sentiment increased to 0.58 in Q3 2017. Its up 0.08, from 0.5 in 2017Q2. It is positive, as 17 investors sold Vince Holding Corp. shares while 7 reduced holdings. 5 funds opened positions while 9 raised stakes. 6.14 million shares or 11.98% less from 6.98 million shares in 2017Q2 were reported. Commercial Bank Of America De has 7,282 shares for 0% of their portfolio. Wells Fargo & Mn has invested 0% in Vince Holding Corp. (NYSE:VNCE). Vanguard Gru Inc holds 0% of its portfolio in Vince Holding Corp. (NYSE:VNCE) for 857,522 shares. J Goldman & Lp owns 750,000 shares or 0.02% of their US portfolio. Meeder Asset Mngmt Inc holds 3,274 shares or 0% of its portfolio. Renaissance Technology Lc reported 0% stake. Invesco accumulated 106,819 shares. Royal Bancorporation Of Canada has 0% invested in Vince Holding Corp. (NYSE:VNCE) for 389 shares. California Public Employees Retirement Sys invested 0% of its portfolio in Vince Holding Corp. (NYSE:VNCE). Geode Cap Management Lc stated it has 131,825 shares or 0% of all its holdings. Morgan Stanley holds 1,708 shares or 0% of its portfolio. 49,302 were reported by Gsa Cap Ptnrs Limited Liability Partnership. Citadel Ltd Liability Corporation reported 24,645 shares. Jpmorgan Chase & Company reported 0% of its portfolio in Vince Holding Corp. (NYSE:VNCE). Barclays Public Ltd Llc holds 0% in Vince Holding Corp. (NYSE:VNCE) or 12 shares.

The stock increased 6.35% or $0.47 during the last trading session, reaching $7.92. About 12,832 shares traded. Vince Holding Corp. (NYSE:VNCE) has declined 92.22% since February 15, 2017 and is downtrending. It has underperformed by 108.92% the S&P500.

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on February, 27. They expect $-1.15 EPS, down 69.12% or $0.47 from last year’s $-0.68 per share. After $-1.04 actual EPS reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.58% negative EPS growth.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $884.81 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.